RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence
Richter, H. E., Amundsen, C. L., Erickson, S. W., Jelovsek, J. E., Komesu, Y., Chermansky, C., Harvie, H. S., Albo, M., Myers, D., Gregory, W. T., Wallace, D., & NICHD Pelvic Floor Disorders Netwo (2017). Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence. Obstetrical & Gynecological Survey, 72(12), 709-711. https://doi.org/10.1097/01.ogx.0000527551.60666.74
Primary treatment approaches for women with urgency urinary incontinence (UUI) include medications and behavioral therapy. Patients with UUI refractory to primary treatments may be offered third-line treatment options such as sacral neuromodulation (SNM) or onabotulinumtoxinA.